Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$236.72
▼ $2.32 (-1.0%)
Market data updated: 09/20 12:47 PM
News analyzed: 09/20/2026
Market Cap
$14.67B
Day Range
$236.06 - $243.68
52-Week Range
$186.05 - $282.15
Beta
—
Next Earnings
06.11.2026
Support
$228.56
Resistance
$276.91
ASND is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+18.7% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 2/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 200
Price is above the 200-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 4.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Ascendis Pharma (ASND) achieves an **investor score of 80** with a **STRONG** rating, driven primarily by a **near-perfect news category score of 100**, reflecting consistent positive developments such as reimbursement wins and patent settlements that reinforce its fair-value narrative. The **technical score of 78** highlights a robust upward momentum, with the stock trading above both its 50-day and 200-day moving averages, a positive MACD histogram, and an RSI of 67.2 indicating healthy upward pressure. However, the stock’s **overbought %K (93.0)** and modest **3-month underperformance (-4.2%) relative to the benchmark** temper optimism. Meanwhile, the **risk score of 50** underscores moderate volatility, with an ATR of 3.0% and a **Clarke Ratio of 1.35**, suggesting a historical volatility range of 39.5% upside and 29.2% downside over three years—indicating potential for significant short-term swings.
The stock exhibits strong bullish technicals, including sustained positions above both the 50-day and 200-day moving averages, a positive MACD histogram, and an RSI of 67.2—all signaling upward momentum. However, the %K reading of 93.0 indicates the stock is overbought, which may limit near-term upside.
Technical strength validates the stock’s current upward trajectory, but overbought conditions could trigger a pullback if momentum stalls.
All recent news items are either neutral or strongly positive, with multiple mentions of reimbursement wins and patent settlements that bolster ASND’s commercial viability and fair-value thesis.
Positive news reinforces investor confidence and justifies the stock’s valuation, but neutral coverage may not fully offset technical or risk-related headwinds.
The ATR of 3.0% and Clarke Ratio of 1.35 (39.5% upside/29.2% downside over three years) highlight moderate volatility and potential for sharp price swings.
While volatility presents opportunities, it also increases the risk of significant short-term declines, particularly if momentum reverses.
StockIQ conclusion
Ascendis Pharma (ASND) demonstrates a **balanced profile** with strong technical and news-driven fundamentals, though risks like overbought conditions and volatility temper its appeal. The stock’s **consistent positive news flow** and **bullish technicals** justify its STRONG rating, but **moderate risk metrics** and relative underperformance highlight potential near-term volatility. Investors should monitor **reimbursement developments** and **technical support levels** to assess whether the current momentum can sustain or if a correction is imminent.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
4d ago · $239.77
Evidence: Panic-selling score jumped from 0 to 26 day-over-day
What happened after
Still awaiting outcome
4d ago · $239.77
Evidence: 1.5x recent average volume
What happened after
Still awaiting outcome
4d ago · $233.25
Evidence: attention score 63/100
What happened after
Still awaiting outcome
4d ago · $233.88
Evidence: -10.6pp vs. sector average today
What happened after
Still awaiting outcome
4d ago · $233.88
Evidence: 9 bullish / 0 bearish technical signals agreeing
What happened after
Still awaiting outcome
17d ago · $267.31
Evidence: FOMO score jumped from 10 to 43 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 10, 2026
Then
78
$260.81
Now
46
$236.72
What happened since
Signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
36
Risk
42
Sentiment
74
Fundamental
No data available
Institutional
80
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Ascendis Pharma A/S has centered on two key developments: its upcoming presentation of pivotal trial data for **TransCon CNP (navepegritide)** in infants with achondroplasia at the **ESPE 2026** conference, highlighting progress in its endocrinology rare disease pipeline. Additionally, the company has resolved a long-standing patent dispute with BioMarin, securing a **global licensing deal** for Yuviwel while agreeing to pay BioMarin **20% U.S. royalties**, alongside a **Canadian reimbursement win for Yorvipath**, reinforcing its commercial and regulatory momentum.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Ascendis Pharma A/S - Ordinary Share. News trend score: 74. Reason: 10 of the last 20 articles are positive, versus 6 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
50
Psychology
46
Fundamentals
—
Technical
36
Valuation
—
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+3%
Market Narrative
43
Fundamental Reality
50
Narrative Gap
-7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant anchoring behavior suggests traders are fixated on the 0.7% resistance gap, likely treating it as a near-term price target. FOMO and euphoria coexist, fueled by strong momentum, overbought RSI, and extreme positive sentiment, but the narrative-reality gap (18 points) hints at potential disconnect between optimism and fundamentals. Herding may emerge if peers rally, while the low panic/selling score indicates no immediate distress. The key question: will traders break resistance or double down on anchoring?
Updated: 09/08/2026, 03:43 PM
What could change this?
👥 What the crowd believes
"BioMarin will receive royalties equal to 20% of U.S. Yuviwel net sales"
"Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath"
"strong price momentum, with a 90-day share price return of..."
"Oppenheimer analyst raises price target to $312"
🧠 Market Brain events driving this
📈 15D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 96/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep methodological differences in how these investors assess risk, data availability, and market conditions. Thorstein Veblen’s high score suggests he sees organic growth aligned with real value creation, while the majority—including Graham, Fisher, and Lynch—struggle due to insufficient fundamental or valuation data, leaving them unable to form a definitive opinion. Meanwhile, cyclical and behavioral investors like Marks (Market Cycle) and Nelson flag late-cycle or overbought risks, contrasting sharply with the cautious but not outright negative stance of Loeb or Bagehot. The efficient-market camp and Schwager’s neutral stance imply no clear edge, while Veblen’s outlier optimism highlights a contrast between structural growth analysis and the more skeptical, data-dependent approaches of the rest.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 82
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 65
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 30
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 28
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A trading range after an advance, but still without clear (volume-based) confirmation of a distribution phase.
Low confidence
$228.56
Range Bottom
$276.91
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 10 positive, 4 neutral, 6 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Benzinga · 14.9.2026
Benzinga · 14.9.2026
Benzinga · 14.9.2026
ChartMill · 14.9.2026
Yahoo · 12.9.2026
Insider Monkey · 12.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Ascendis Pharma A/S - Ordinary Share (ASND) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for ASND specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
ASND's technical score is 36/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 200-day average; +0.5% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: ATR: 4.3% of price; Price is below the 50-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for ASND.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 16 purchases and 4 sales out of the last 22 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Bodenhoff Mads | Open Market Sale | 8.9.2026 | 3,000 | -3,000 | $270.19 |
| Bodenhoff Mads | Exercise of Derivative Securities | 8.9.2026 | 3,000 | -3,000 | — |
| Bodenhoff Mads | Exercise of Derivative Securities | 8.9.2026 | 3,000 | +3,000 | $110.00 |
| HOLTUG LARS | Open Market Sale | 2.9.2026 | 236 | -236 | $264.13 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 14.8.2026 | 900 | +900 | $246.91 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 14.8.2026 | 1,100 | +1,100 | $245.85 |
| SMITH SCOTT THOMAS | Open Market Purchase | 2.6.2026 | 100 | +100 | $219.00 |
| SMITH SCOTT THOMAS | Open Market Purchase | 2.6.2026 | 4,367 | +100 | $219.00 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 100 | +100 | $223.50 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 200 | +200 | $223.76 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 200 | +200 | $222.30 |
| SMITH SCOTT THOMAS | Open Market Purchase | 29.5.2026 | 250 | +250 | $223.32 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 600 | +200 | $223.76 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 800 | +200 | $222.30 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 29.5.2026 | 900 | +100 | $223.50 |
| SMITH SCOTT THOMAS | Open Market Purchase | 29.5.2026 | 4,267 | +250 | $223.32 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 26.5.2026 | 200 | +200 | $236.24 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 26.5.2026 | 200 | +200 | $239.37 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 26.5.2026 | 200 | +200 | $236.24 |
| BIENAIME JEAN JACQUES | Open Market Purchase | 26.5.2026 | 400 | +200 | $239.37 |
| JENSEN FLEMMING STEEN | Open Market Sale | 11.5.2026 | 19,460 | -19,460 | $238.49 |
| JENSEN FLEMMING STEEN | Open Market Sale | 11.5.2026 | 0 | -19,460 | $238.49 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,203,221 shares short as of 2026-08-31 · vs. 3,404,687 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.5% of trading volume this week was short selling, vs. 67.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology